Innovation Through Collaboration
Mirati is seeking collaboration opportunities to identify and advance novel approaches to treating oncology with a focus on agents that target key signaling pathways involved in tumor growth and development.
Our Regional Partnerships in Asia
In June 2021, Mirati Therapeutics Inc. and Zai Lab announced a collaboration and license agreement for adagrasib (MRTX849), a small-molecule KRASG12C inhibitor, in Greater China (mainland China, Hong Kong, Macau and Taiwan). Under the terms of the agreement, Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China.
Mirati received an upfront payment and is eligible to receive milestone payments based upon the achievement of certain development, regulatory and sales-based milestone, as well as tiered royalties with percentages ranging from high teen to low twenties on future sales adagrasib in Greater China.
In January 2018, Mirati and Beigene announced an exclusive license agreement for the development, manufacturing and commercialization of Mirati's sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati retained exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world.
Mirati is eligible to receive milestone payments based upon the achievement of certain development, regulatory and sales milestones as well as significant royalties on future sales of sitravatinib in the licensed territory.
Our Clinical Collaborations
In October 2021, Mirati and Sanofi announced a clinical collaboration to evaluate the combination of adagrasib, Mirati's investigational KRASG12C inhibitor, with Sanofi's investigational SHP2 inhibitor SAR442720, also known as RMC-4630, in a Phase 1/2 dose escalation and expansion study in patients with previously-treated non-small cell lung cancer and KRASG12C mutations.
Under the terms of the non-exclusive collaboration, Sanofi will be responsible for sponsoring and operating the study, and jointly with Mirati, will oversee and share costs of the study.
In September 2020, Mirati and Boehringer Ingelheim announced a clinical collaboration to evaluate the investigational combination of BI 1701963, a SOS1::pan-KRAS inhibitor, and adagrasib (MRTX849), a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation.
Under the terms of the non-exclusive collaboration, Mirati will be the sponsor of the trial and Boehringer Ingelheim and Mirati will jointly share the costs of and oversee clinical development for the combined therapy.
In July 2019, Mirati and Novartis announced a clinical collaboration agreement to evaluate the combination of adagrasib (MRTX849), Mirati's investigational KRAS G12C inhibitor and TNO155, Novartis' investigational SHP2 inhibitor, in patients with advanced solid tumors that harbor KRAS G12C mutations.
Under terms of the non-exclusive collaboration, Mirati will sponsor the trial and Novartis and Mirati will jointly oversee and share the costs of clinical development activities for the combined therapy. Novartis will provide TNO155 at no cost.
In January 2019, Mirati and Bristol Myers Squibb announced a clinical collaboration to evaluate the investigational combination of sitravatinib and nivolumab (OPDIVO®), in a Phase 3 trial in second line non-small cell lung cancer patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.
Under the terms of the collaboration, Mirati will sponsor and fund the clinical trial and Bristol Myers Squibb will provide nivolumab at no cost. Mirati maintains global development and commercial rights to sitravatinib outside of certain Asian territories, where it is partnered with BeiGene, and is free to develop the program in combination with other agents.
bd@Mirati.com